Nanoform signs GMP manufacturing program with TargTex following formulation success
Press release Nanoform Finland Plc February 4, 2022 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform signs GMP manufacturing program with TargTex following formulation success Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP[1] manufacturing program (clinical development) to enhance TargTex’s Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) phase. This follows a successful PoC (Proof of Concept) study where the hydrogel formulation developed by Nanoform (